Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.49 |
| ▸ | RECQL | P46063 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 11/20 | 0.46 |
| ▸ | CA1 | P00915 | 10/20 | 0.46 |
| ▸ | CA9 | Q16790 | 9/20 | 0.46 |
| ▸ | CA12 | O43570 | 4/20 | 0.46 |
| ▸ | CA7 | P43166 | 4/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.46 |
| ▸ | CA3 | P07451 | 2/20 | 0.46 |
| ▸ | CA4 | P22748 | 2/20 | 0.46 |
| ▸ | CA6 | P23280 | 2/20 | 0.46 |
| ▸ | CA5A | P35218 | 2/20 | 0.46 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8921158 | 1.00 | TSHR (0.49) | TSHRRECQLMAPK1GLAHPGD | |
| SCHEMBL8920377 | 1.00 | TSHR (0.49) | TSHRRECQLMAPK1GLAHPGD | |
| SCHEMBL8915955 | 1.00 | TSHR (0.49) | TSHRRECQLMAPK1GLAHPGD | |
| SCHEMBL8926435 | 1.00 | TSHR (0.49) | TSHRRECQLMAPK1GLAHPGD | |
| SCHEMBL10870886 | 1.00 | TSHR (0.49) | TSHRRECQLMAPK1GLAHPGD | |
| SCHEMBL4192257 | 0.98 | RECQL (0.46) | TSHRRECQLMAPK1GLAHPGD | |
| SCHEMBL27649743 | 0.93 | CA2 (0.46) | TSHRRECQLMAPK1GLAHPGD | |
| SCHEMBL27995614 | 0.91 | RECQL (0.57) | TSHRRECQLMAPK1GLAHPGD | |
| SCHEMBL27520719 | 0.91 | RECQL (0.57) | TSHRRECQLMAPK1GLAHPGD | |
| SCHEMBL27550478 | 0.90 | RECQL (0.55) | TSHRRECQLMAPK1GLAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1712601-B1 | Phase change inks | XEROX CORP (US) | 2010-07-28 | — | — | EP | claimed |
| US-6461417-B1 | Ink compositions | XEROX CORPORATION | 2002-10-08 | — | — | US | claimed |
| US-6398857-B1 | ACCUSTIC PIEZOELECTRIC; HOT MELT INK JET PRINTING; BENZOIC ACID VEHICLE; ALKYL OR PHENYL CARBOXYLIC ACID VISCOSITY MODIFIER; RETAINS DESIRED HARDNESS | XEROX CORPORATION | 2002-06-04 | — | — | US | claimed |
| US-6187083-B1 | INK COMPOSITION COMPRISING SELECTED INK VEHICLE, AMIDE VISCOSITY MODIFIER, CONDUCTIVE SULFONATE SALT ALL HAVING MELTING POINTS WITHIN SPECIFIED RANGE, COLORANT, OPTIONAL ANTIOXIDANT AND ULTRAVIOLET ABSORBER | XEROX CORPORATION | 2001-02-13 | — | — | US | claimed |
| US-9597416-B2 | Fluorescent membrane intercalating probes and methods for their use | PHANOS TECHNOLOGIES, INC. (US) | 2017-03-21 | — | — | US | disclosed |
| US-20150044143-A1 | FLUORESCENT MEMBRANE INTERCALATING PROBES AND METHODS FOR THEIR USE | PHANOS TECHNOLOGIES, INC. (US) | 2015-02-12 | — | — | US | disclosed |
| US-8894976-B2 | Fluorescent membrane intercalating probes and methods for their use | PHANOS TECHNOLOGIES, INC. (US) | 2014-11-25 | — | — | US | disclosed |
| EP-1985672-B1 | Phase Change Ink Compositions | XEROX CORP (US) | 2011-02-09 | — | — | EP | disclosed |
| US-7811370-B2 | Phase change ink compositions | XEROX CORPORATION (US) | 2010-10-12 | — | — | US | disclosed |
| EP-1712601-B1 | Phase change inks | XEROX CORP (US) | 2010-07-28 | — | — | EP | disclosed |
| EP-1535974-B1 | Processes for preparing phase change inks | XEROX CORP (US) | 2010-03-31 | — | — | EP | disclosed |
| US-20090304598-A1 | FLUORESCENT MEMBRANE INTERCALATING PROBES AND METHODS FOR THEIR USE | PHANOS TECHNOLOGIES, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-5241027-A | MACROMOLECULAR SPIROPYRAN COMPOUNDS | OTSUKA KAGAKU KABUSHIKI KAISHA (JP) | 1993-08-31 | — | — | US | disclosed |
| US-5236958-A | BENZOSELENAZOLINO-VINYLSPIROPYRAN COMPOUND | OTSUKA KAGAKU KABUSHIKI KAISHA (JP) | 1993-08-17 | — | — | US | disclosed |
| EP-0470264-A1 | BENZOSELENAZOLINE-SPIRO-VINYLPYRAN COMPOUND AND POLYMER COMPRISING THE SAME | OTSUKA KAGAKU KABUSHIKI KAISHA (JP) | 1992-02-12 | — | — | EP | disclosed |
| EP-0466938-A1 | HIGH-MOLECULAR SPIROPYRAN COMPOUND | OTSUKA KAGAKU KABUSHIKI KAISHA (JP) | 1992-01-22 | — | — | EP | disclosed |
| US-5008405-A | Selective etherification | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1991-04-16 | — | — | US | disclosed |
| EP-0379968-A2 | Selective etherification | Takeda Chemical Industries, Ltd. (JP) | 1990-08-01 | — | — | EP | disclosed |
| US-4804613-A | PHOTOPOLYMERIZABLE MONOMER; ERASABLE | CANON KABUSHIKI KAISHA (JP) | 1989-02-14 | — | — | US | disclosed |
| US-4766047-A | USING PHOTO POLYMERIZABLE MONOMER WITH HYDROPHOBIC AND HYDROPHILIC GROUPS AND UNSATURATED BOND | CANON KABUSHIKI KAISHA (JP) | 1988-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090304598-A1 | FLUORESCENT MEMBRANE INTERCALATING PROBES AND METHODS FOR THEIR USE | TIMM44, SLC47A2, TIMM50 | TSHR 3098/4885RECQL 579/4885MAPK1 4760/4885 |
| US-20150044143-A1 | FLUORESCENT MEMBRANE INTERCALATING PROBES AND METHODS FOR THEIR USE | TIMM44, SLC47A2, TIMM50 | TSHR 3098/4885RECQL 579/4885MAPK1 4760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.